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Background: Asherman syndrome (AS) is characterized by the presence of adhesions in the 
uterine cavity. Clinical presentation includes amenorrhea/hypomenorrhea and dysmenorrhea. It is 
associated with a high rate of infertility and pregnancy complications. 
Objective: To provide an update on the management of AS, with special regard to the future 
perspectives on treatment and prevention of recurrence. 
Study	design: Literature review. 
Search	 methods: A literature search was conducted using MEDLINE, PubMed and The 
Cochrane Library electronic resources. The searched keywords included the terms “Asherman's 
syndrome”, “Asherman syndrome”, “intrauterine synechiae”, “uterine synechiae” and 
“intrauterine adhesions”. The search was restricted to studies published in the last 5 years and 
written in English or French languages. 
Discussion: Comprehensive management, consisting in hysteroscopic adhesiolysis followed by 
postoperative prevention of recurrence, provides the best possible outcomes. New developments 
in hysteroscopy, such as ultrasound guidance and office hysteroscopy, have contributed to an 
overall success rate of 95% and a low rate of complications. However, intrauterine adhesions 
(IUAs) recurrence is a major problem, occurring in 28.7% of patients who had successful 
adhesiolysis. Several methods to prevent IUAs recurrence have been proposed: (1) mechanical 
devices, including various types of intrauterine balloons and intrauterine devices; (2) 
postoperative estrogen therapy; (3) barrier gels (hyaluronic acid and its derivates) and (4) human 
amniotic membrane grafting. 
Stem cells (SCs), specifically bone marrow-derived SCs, have been explored as a new therapeutic 
strategy in AS, with promising results. However, more randomized controlled studies are needed 
to confirm these results. 
Conclusions: Hysteroscopic adhesiolysis is the established gold standard for IUAs treatment, 
with proven safety and efficacy. Over the last years, the focus has been on the prevention of IUAs 
recurrence, with the development of several effective methods. Finally, recent experimental 
studies highlight SCs therapy as a promising therapeutic option for AS. 
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Contextualização: O síndrome de Asherman (SA) é caracterizado pela presença de sinéquias na 
cavidade uterina. O quadro clínico inclui amenorreia/hipomenorreia e dismenorreia. Associa-se a 
uma elevada taxa de infertilidade e de complicações da gravidez. 
Objetivo: Rever a abordagem terapêutica do SA, com especial destaque para as futuras opções 
terapêuticas e de prevenção das recorrências. 
Desenho	do	estudo: Revisão da literatura.  
Métodos	 de	 pesquisa: A pesquisa foi efetuada com recurso às bases de dados MEDLINE, 
PubMed e The Cochrane Library. Foram utilizadas as seguintes palavras-chave: “Asherman's 
syndrome”, “Asherman syndrome”, “intrauterine synechiae”, “uterine synechiae” e “intrauterine 
adhesions”. A pesquisa restringiu-se a estudos publicados nos últimos 5 anos, escritos em língua 
inglesa ou francesa. 
Discussão: Uma abordagem compreensiva, englobando a lise histeroscópica das sinéquias 
seguida da prevenção pós-operatória das recorrências, permite otimizar os resultados alcançados. 
Os novos avanços no âmbito da histeroscopia, nomeadamente a histeroscopia eco-guiada e a 
histeroscopia de ambulatório, contribuíram para uma taxa de sucesso global de 95%, associada a 
uma baixa taxa de complicações. No entanto, a recorrência das sinéquias é um problema major, 
ocorrendo em 28.7% das doentes. Vários métodos para a prevenção das recorrências têm sido 
propostos: (1) dispositivos mecânicos, incluindo vários tipos de balões e dispositivos 
intrauterinos; (2) terapêutica pós-operatória com estrogéneos; (3) géis de efeito barreira (ácido 
hialurónico e derivados) e (4) enxertos de membrana amniótica humana. 
A terapia com célula estaminais (CEs), nomeadamente com CEs derivadas da medula óssea, tem 
sido amplamente estudada no âmbito do SA, com resultados promissores. No entanto, é 
necessário um maior número de estudos aleatorizados e controlados para confirmar estes 
resultados.  
Conclusões: A lise histeroscópica é considerada o gold standard no tratamento das sinéquias 
uterinas, com eficácia e segurança demonstradas. Ao longo dos últimos anos, tem sido dado 
especial enfoque à prevenção da recorrência das sinéquias, com o desenvolvimento de vários 
métodos preventivos eficazes. Por fim, estudos experimentais recentes têm destacado a terapia 
com CEs como uma opção terapêutica promissora.  
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Asherman syndrome (AS), described 
in 1948 by Joseph Asherman1, is an acquired 
condition characterized by the presence of 
adhesions in the uterine cavity. Women with 
this disease may present with menstrual 
irregularities (amenorrhea or 
hypomenorrhea), dysmenorrhea, infertility, 
recurrent pregnancy losses and history of 
abnormal placentation.2,3 The terms 
‘Asherman syndrome’ and ‘intrauterine 
adhesions’ (IUAs) are often used 
interchangeably. However, some filmy IUAs 
are clinically inconsequential. Therefore, 
and according to the original definition of 
the syndrome, some authors prefer to reserve 
the term ‘Asherman syndrome’ to 
symptomatic patients.2,4,5  
Although uterine curettage following 
miscarriage or retained products of 
conception (RPOC) is the most common 
predisposing factor, any uterine injury can 
cause IUAs.5–7 For example, uterine 
compression suturing during postpartum 
hemorrhage has a high rate of IUAs 
development (16% to 18.5%).8–11 Also 
hysteroscopic metroplasty for uterine septum 
correction and treatment of symptomatic 
myomas – both open and hysteroscopic 
myomectomy and uterine artery 
embolization – are associated to IUAs 
development.12–15 The role of infection as a 
cause of IUAs still remains unclear, 
regarding the limited number of related 
studies.3 However, genital tuberculosis and 
schistosomiasis have been associated to 
IUAs development.6,16,17 
In the general population AS is a rare 
condition. However, it is reported an 
incidence of 13% in women undergoing 
routine infertility investigations and of 7% in 
women with secondary amenorrhea.18,19 An 
increase in the number and complexity of 
uterine surgical procedures, as well as the 
increased awareness and more detailed 
diagnostic approaches, is contributing to a 
higher number of reported cases.20 
 Taking into account the reproductive 
impact of this condition, with a high rate of 
infertility and pregnancy complications, the 
aim the current review is to provide an 
update on the management of AS, with 
special regard to the future perspectives on 





 A literature search was conducted in 
September/October 2016 using MEDLINE, 
PubMed and The Cochrane Library 
electronic resources. The searched keywords 
included the MeSH (Medical Subject 
Headings) terms “Asherman's syndrome”, 
“Asherman syndrome”, “intrauterine 
synechiae”, “uterine synechiae” and 
“intrauterine adhesions” combined using the 
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operator “OR”. The search was restricted to 
studies published in the last 5 years and 





162 studies were found. Among 
those, 58 studies were selected according to 
their clinical relevance and suitability. 
References of selected studies were 
examined to identify additional relevant 
literature not found by the initial searches. 
Relevant references were also included in 
this review, without any published date 
restriction.  By the end of the selection 
process, a total of 87 studies were included, 
with the following designs: 11 randomized 
controlled studies; 20 retrospective cohort 
studies; 13 prospective cohort studies; 1 
case-control study; 4 basic research studies; 
10 systematic reviews; 22 non-systematic 








The impact of AS on pregnancy is 
well documented with a high rate of 
infertility and pregnancy complications such 
as placental abruption, preterm premature 
rupture of membranes (PROM), abnormal 
placentation and recurrent spontaneous 
abortions. Some etiologies of infertility are 
easy to explain, such as obstruction of the 
tubal ostia or endocervix. Other mechanisms 
include reduced uterine cavity size, poor 
endometrial receptivity, myometrial fibrosis, 
and reduced uterine blood flow.7  
In a retrospective cohort study 
published in 201221, women with IUAs were 
more than threefold more likely to have 
placental abruption and more than twofold 
more likely to have preterm PROM when 
compared with women without IUAs. They 
were also nearly twofold more likely to have 
cesarean delivery for malpresentation. 
Although a causal relationship between 
IUAs and these pregnancy complications is 
not proved yet, it seems to be biologically 
plausible. Placental implantation near the 
poorly vascularized adhesions may 
predispose to placental abruption and the 
wrapping of fetal membranes around IUAs 
may lead to premature rupture as the uterus 
enlarges. Furthermore, the presence of IUAs, 
especially when large, may distort the 
uterine cavity, resulting in malpresentation 
and the need for cesarean delivery.21,22 
IUAs are also related to abnormal 
placentation, namely placenta accreta, due to 
trauma of the endometrium with defects in 
the basal decidua. Consequently, pregnant 
patients with IUAs should be thoroughly 
examined for possible abnormal placentation 
and, in case of suspicion, the patient should 
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be scheduled for planned cesarean due to 
risk of severe postpartum hemorrhage.23 
A 2012 prospective study24 including 
265 women with recurrent pregnancy loss 
(RPL), defined as two or more consecutive 
miscarriages, has found an incidence of 
IUAs of 7% in this population. There is 
some evidence that adhesions can cause RPL 
by mechanisms such as diminished 
functional intrauterine volume and 
endometrial fibrosis, which restricts 
expansion. Therefore, diagnostic 
hysteroscopy with eventual adhesiolysis is 





Hysteroscopy remains the gold 
standard in the assessment of IUAs. It 
provides a direct visualization of the uterine 
cavity, allowing for a meticulous 
characterization of the adhesions and 
offering the possibility of an immediate 
treatment. Before the advent of 
hysteroscopy, hysterosalpingography (HSG) 
was the main method for the diagnosis of 
IUAs. The information provided by HSG is 
limited and the high rate of false-positive 
diagnoses, coupled with radiation exposure 
and invasiveness are the main disadvantages 
of this diagnostic tool.3,4 
Imaging methods such as ultrasound 
and saline infusion sonography (SIS) have 
gained popularity as less invasive diagnostic 
tools. 2D-Ultrasound has shown a high 
sensitivity for IUAs diagnosis, although its 
specificity is very low (97% and 11%, 
respectively). 3D-Ultrasound has proved to 
be superior (with a sensitivity and specificity 
of 87% and 45%, respectively), as it 
provides panoramic views of the uterine 
cavity in the coronal plane, with much 
clearer views of the endometrial-myometrial 
junction.4,25 
SIS is less invasive than 
hysteroscopy and almost devoid of 
complications. Furthermore, it allows for 
identification of eventual extra-uterine or 
adnexal pathology, it is cheaper, relatively 
easy to perform and better tolerated than 
hysteroscopy.26–28 However, it does not 
allow for concurrent treatment of IUAs.29 
According to a systematic review and meta-
analyses published in 2015,27 the sensitivity 
and specificity of SIS in the detection of 
IUAs were 82% and 99%, respectively. 
Therefore, they recommend that SIS should 
become the first-line screening tool in the 
assessment of subfertile women.  
A number of classification systems 
have been developed to grade the adhesions 
in terms of severity. The widely used 
classification of the American Fertility 
Society (1988)30 takes into account the 
hysteroscopic/ hysterosalpingographic 
aspect of IUA and the menstrual pattern 
(Table 1). More recently, in 2000, it was 
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published a clinicohysteroscopic scoring 
system,31 which include not only the 
menstrual symptoms but also the obstetric 
history of the patient (Table 2). Studies of 
reproductive outcomes using these 
classification systems have not been reported 
yet. Therefore, there is still no clear 






The primary goal of the management 
of AS is to restore the uterine cavity to its 
normal size and shape and stimulate 
regeneration of the destroyed endometrium. 
Secondary goals include treating associated 
symptoms (including infertility) and 
preventing adhesions recurrence.20,32 
Comprehensive management provides the 
best possible outcomes, especially in poor-
prognosis women with severe adhesions. 
This approach involves operative treatment 
of IUAs followed by postoperative 
prevention of recurrence.33,34 
Centralization of care is also very 
important, as AS is a rare disease and its 
operative treatment is a difficult procedure 
with potential complications. Centralization 
allows to reach higher volumes of patients 
per center and therefore to improve success 
rates and to stimulate the research, especially 
randomized clinical trials that do not suffer 
from lack of recruitment.35  
1.	OPERATIVE	TREATMENT	
	
 Dilatation and curettage (D&C) was 
widely used before the widespread use of 
hysteroscopy. Nowadays it is still used at 
centers with limited resources. A 
retrospective study published in 201536, 
including 100 cases of AS managed at a 
center in Nigeria has shown that blind D&C 
has a relatively poor outcome, with 
correction of menses seen in just 37.2% of 
the patients and a pregnancy rate of 32.1%. 
Also, D&C is associated with a high risk of 
uterine perforation and should therefore be 
considered obsolete.3,20,37  
Hysteroscopic adhesiolysis (HA) is 
the established gold standard for IUAs 
treatment because of its minimally invasive 
nature and because it can be performed 





Mechanical instruments or energy 
sources (monopolar/bipolar energy or laser) 
can be used in HA. The mechanical 
approach with scissors is the most accessible 
method, with a low cost. It allows separation 
of the adhesions without thermal damage of 
the surrounding normal endometrium, thus 
reducing the rate of perforation during the 
procedure. In case of perforation, the risk of 
visceral injury is lower when compared to 
energy sources. Another advantage of 
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hysteroscopic scissors is the use of a smaller 
hysteroscope without the need of dilatation. 
As a disadvantage, scissors may become 
blunt easily with compromised cutting 
ability and are not able to stop eventual 
bleeding. In contrast, the use of energy 
sources is associated with potential thermal 
damage to the residual endometrium, 
although it provides effective and precise 
cutting as well as good hemostasis. Thermal 
damage of endometrium may be limited by 
using the minimal amount of energy.19,37–39  
Electrosurgical instruments include 
the bipolar electrode Versapoint® and 
resectoscopes using monopolar or, more 
recently, bipolar current. The distending 
media used with monopolar current has to be 
a non-electrolyte, non-conductive solution, 
such as glycine 1.5%, sorbitol 3-5%, or 
mannitol 5%. Absortion of large volumes of 
these fluids may result in fluid overload with 
hypervolemia, hyponatremia, hypo-
osmolarity, pulmonary edema and cerebral 
edema, although these major complications 
are extremely rare. Bipolar energy has the 
advantage that isotonic solutions (normal 
saline and lactated Ringer) can be used as 
distension medium, decreasing the risks of 
fluid absorption. Fluid input and output 
should still be monitored and if excessive 
intravasation occurs, the fluid overload is 
generally readily treatable with intravenous 
diuretics. The main disadvantage of bipolar 
compared with monopolar electrodes is the 
higher number of gas-bubbles that are 
created, disturbing visibility.19,40 
A 2013 case-control study,41 
including 1842 hysteroscopic procedures, 
has compared the complication rates of 
hysteroscopic surgery performed using 
monopolar and bipolar energy. They 
concluded that both techniques are safe, with 
no statistically significant difference in 
complication rates between the two groups 
(4.1% and 2.8%, respectively; P-value = 
0.08). However, because of the previously 
mentioned fluid overload complications, the 
authors recommend that bipolar system 
should be preferred when available.  
Lasers (e.g. neodymium-doped 
yttrium aluminium garnet [Nd-YAG], 
potassium-titanyl-phosphate [KPT] and 
argon) offer no advantages over 
electrocoagulation. As these lasers have a 
significant risk of thermal damage, are more 
expensive and not readily available in all 
hospitals, their use has almost 
disappeared.19,40 
Since no randomized controlled 
studies have been published specifically on 
HA techniques, different treatment 
modalities for IUAs are based on individual 
experience.40 Some surgeons use a 
combination of both mechanical and 





As previously mentioned, HA carries 
a significant risk of uterine perforation, 
especially during the dilatation of the 
cervical channel and introduction of the 
hysteroscope. To avoid this complication 
and to improve the likelihood of complete 
resection, laparoscopic and, more recently, 
ultrasound guidance have been used.37 
According to a 2012 retrospective cohort 
study42 including a total of 159 
hysteroscopic procedures, transabdominal 
ultrasound guidance significantly decreases 
the risk of perforation, with an incidence of 
1.9% contrasting to 8.7% with laparoscopic 
guidance and 5.3% with no guidance. All 
perforations in the laparoscopic-guidance 
group occurred after insertion of the 
laparoscope, while in the ultrasound-
guidance group they occurred prior to 
carrying out ultrasonography; when 
ultrasound was used properly, no uterine 
perforation occurred. Also, ultrasound 
guidance costs less than laparoscopic 
guidance and adds no cost to conventional 
hysteroscopy without guidance. Ultrasound 
is therefore the optimal mean of assisting 





Hysteroscopic lysis releases the 
traction exerted by the IUAs and decreases 
the resistence against subendometrial blood 
flow, thereby stimulating endometrial 
healing and increasing endometrial 
thickness, which is essential for a good 
endometrial receptivity and successful 
fertility treatments.43,44 A prospective study 
published in 201313 has concluded that 67% 
and 96% of women achieved a complete 
endometrial recovery 1 month and 2 months 
after HA, respectively. Therefore, they 
recommend a waiting period for subsequent 
fertility treatment of 3 months. However, it 
should be noted that severe and extensive 
IUAs take a longer time to complete the 
endometrial recovery process, as their 
treatment must sometimes be performed in 
several separate procedures. Each new 
procedure results in new wounds and healing 
process resumes. It could be hypothesized 
that these repetitive interventions would 
cause worse reproductive outcomes or a 
higher rate of complications. However, a 
retrospective case series study45  including 
23 women with AS who required more than 
two hysteroscopic adhesiolysis procedures 
has concluded that it is appropriate to treat 
women until visualization of both uterine 
ostia is possible, even if multiple HA 
procedures are needed. With respect to 
fertility outcomes, namely pregnancy rate, 
no significant difference was observed 
between the groups who underwent three, 
four and five procedures (45.5%, 37.5% and 
50%, respectively; P-value = 1). Thus, the 
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number of hysteroscopic procedures should 
not be a limiting factor.  
The most recent data regarding the 
efficacy and reproductive outcomes of HA 
comes from a large cohort study published in 
201535, including a total of 638 women with 
AS operated between 2003 and 2013. 
According to this study, the overall success 
rate of HA, which includes restoration of 
both normal uterine anatomy and menses, 
achieved 95%. Among patients who had 
successful HA, 28.7% had spontaneous 
adhesion recurrence. Also, multivariate 
analysis has shown that higher grades of 
adhesions were predictive of a higher chance 
of IUAs recurrence, when compared to low 
grades (P-value = 0.013). Besides the grade 
of IUAs, the success of HA also depends on 
their etiology. A 2014 retrospective cohort 
study39 including 76 patients has shown that 
IUAs following uterine artery embolization 
have a significantly poorer prognosis than 
IUAs caused by trauma, with a higher 
grading score at second look hysteroscopy, 
less improvement in menstrual pattern and 
reduced conception and live birth rates. 
According to another retrospective cohort 
study published in 201546, including 115 
women, there is also an association between 
the location and extent of IUAs and 
postoperative adhesion recurrence, with a 
higher risk when original adhesions are 
located at the uterine cornua, at the cervico-
isthmic region and when a large portion of 




With the new developments in 
hysteroscopy, namely the reduction of 
instruments size, OH in an outpatient setting 
has begun to replace the conventional 
hysteroscopy performed in operating-
room.40 A small retrospective series47 
including 20 cases of AS has shown that 
these patients may be successfully treated by 
OH without general or regional anesthesia. 
After the treatment, 84% of the patients had 
no adhesion or just mild adhesions, all of 
them achieved normal menses, 6 had a 
spontaneous pregnancy and 5 went on to 
have a term delivery to date. In 94.6% of 
cases oral analgesia was sufficient to pain 
control (89% nonsteroidal anti-inflammatory 
drugs; 5.6% oral lorazepam). Consequently, 
the anesthetic risk is very low, with faster 
return to work, decreased cost and high 
patient satisfaction with their procedure 
experience and analgesia control.47–49 
Furthermore, according to a 2012 
retrospective cohort study50 including 1028 
procedures, OH is safe, with a low 
complication rate during the procedure and 
an extremely low risk of long-term 
complications (0.001%), namely infection, 
in either diagnostic or therapeutic 
procedures. Therefore, there is no indication 
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for prophylactic antibiotics or antiseptical 
measures.  
Vaginoscopic approach is the 
currently used technique in the outpatient 
setting. Patient is placed in the lithotomy 
position and the hysteroscope is inserted 
through the internal cervical orifice under 
direct endoscopic vision, without the need of 
a speculum. Ideally, this is carried out with 
no, or minimal, cervical dilatation.40 A 
systematic review with meta-analysis51 of 4 
randomized studies has proved that 
vaginoscopic approach is less painful than 
the traditional technique using a vaginal 
speculum, which is clearly advantageous in 
outpatient procedures to optimize 
acceptability to patients. However, 
traditional approach with a vaginal speculum 
and possibly cervical instrumentation is still 
necessary in the minority of cases in which 
visualization of the cervical canal is difficult 





Evaluation of uterine cavity after HA 
is an important step in AS management, as 
timely recognition of adhesion recurrence is 
essential to provide the best prognosis.3 
Hysteroscopy, particularly OH, is the most 
commonly used follow-up method, as it 
permits immediate treatment of reformed 
adhesions.3,13,46 Although there is no clear 
consensus, follow-up is recommended one-





As mentioned in the last section, 
adhesion recurrence is one of the major 
problems following HA. Several methods to 
prevent IUAs recurrence have been 
proposed, including (1) mechanical devices, 
(2) medical therapies, (3) anti-adhesion 
barrier gels and (4) human amniotic 
membrane grafting. 
According to a Cochrane Database 
systematic review published in 201552 and 
including 11 randomized studies, anti-
adhesion therapy was associated with fewer 
IUAs at second-look hysteroscopy when 
compared with no treatment or placebo (P 
value = 0.0005) (Figure 1), although no 
differences were found with respect to live 
birth rates (P value = 0.98) (Figure 2). 
However, the methodological quality of 
most of the included studies (9 of 11) was 
low, which may compromise the results of 




Mechanical devices include various 
types of intrauterine balloons and 
intrauterine devices (IUDs). They help to 
keep opposing surfaces of the uterine cavity 
separate and the subsequent removal of the 
IUD may also help to remove some 
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adhesions that may have reformed.53 Next 
paragraphs describe the currently available 
intrauterine balloons (Foley’s catheter and 
heart-shaped balloon) and IUDs (T-shaped, 
Lippes loop and heart-shaped IUD) and their 
outcomes. 
Foley’s catheter balloon was one of 
the first mechanical devices used for 
prevention of adhesion recurrence.3 Due to 
its spherical shape, it is not likely to fit into 
the uterine sidewall and corneal region and 
therefore may not be an effective barrier in 
these regions.54 A small retrospective cohort 
study55 including 26 women who underwent 
open myomectomy during which the uterine 
cavity was breached reported no IUAs 
formation (0%) in the group treated with 
Foley’s catheter following breach of uterine 
cavity, compared to a rate of 30% of IUAs 
formation in controls. However, there are no 
randomized controlled trials attesting its 
efficacy and there is risk of uterine 
perforation and ascending infection.3 Thus, 
American Association of Gynecologic 
Laparoscopists does not recommend Foley’s 
catheter routine use outside of clinical 
trials.56  
The heart-shaped uterine balloon 
(Cook Medical balloon) is a silicone made, 
triangular shape device. It was specially 
designed for IUAs prevention and fits the 
normal shape of the uterine cavity. However, 
it is more difficult to insert and more 
expensive than Foley’s catheter.3,54 One 
potential risk of intrauterine balloon is 
ascending infection. However, a 2014 
prospective, randomized, controlled study57 
including 60 women who underwent 
hysteroscopic surgery has proved that 
bacterial colonization did not increase 
significantly after 30 days, in both 
intrauterine balloon group and control group. 
All the identified bacteria represent normal 
vaginal flora and no woman developed 
pelvic inflammatory disease. Therefore, 
intrauterine balloon may be placed in uterus 
for up 30 days without increased risk of 
infection. This result is compatible with the 
American College of Obstetricians and 
Gynecologists guidelines against routine 
antibiotic prophylaxis following 
hysteroscopic surgery.58 
Lippes loop IUD was favored for 
prevention of IUAs due to its large area but 
is no longer available in many countries.52,59 
T-shaped IUD has no contact with the 
sidewall, and so is not expected to be 
effective in preventing marginal adhesions.54 
Heart-shaped copper IUD is a semi-flexible, 
stainless steel device impregnated with 
copper and anti-inflammatory agent. Due to 
its shape, it also fits well in the uterine 
cavity, pressing against the lateral wall.54   
A systematic review published in 
201459  and including 28 studies has 
concluded that IUDs are safe and effective 
but they need to be combined with other 
ancillary treatments (hormonal, anti-
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adhesions barrier gels or amnion graft) to 
obtain maximal outcomes, particularly in 
patients with moderate to severe IUAs. This 
review also alerts for the lack of evidence 
about the ideal IUD, the duration course of 
IUD therapy and the stage of adhesion in 
which IUD therapy will be most beneficial.  
According to a 2015 prospective, 
randomized, controlled study54  including 
201 women with AS, heart-shaped 
intrauterine balloon and heart-shaped copper 
IUD appear to be of similar efficacy in the 
prevention of IUAs recurrence after HA, 
with no significant differences in the median 
adhesion score reduction and in the adhesion 
reformation rate.  
A retrospective cohort study53 
including 107 women has shown that both 
heart-shaped balloon and copper coil IUD 
achieved greater results in adhesion 
recurrence prevention after HA than 
hyaluronic acid gel (P value < 0.001), which 
results are similar to the control groups. 
However, a carefully designed randomized 
controlled study is needed to confirm the 




 Hormonal therapy with estrogen 
stimulate the remodeling and proliferation of 
endometrium by up-regulating the 
expression of growth factors, such as 
vascular endothelial growth factor (VEGF), 
basic fibroblast growth factor (bFGF) and 
transforming growth factor (TGF-β1).32 
 Estrogen administration can be 
performed preoperatively and 
postoperatively. Preoperative administration 
stimulates endometrial proliferation so that 
endometrium would be seen at 
transabdominal ultrasound guidance when 
HA is performed, reducing the risk of 
perforation. However, an overly stimulated 
endometrium would difficult the 
visualization of the ostial tube. There is lack 
of good-quality evidence confirming the 
efficacy of preoperative estrogen and 
establishing proper protocols.32 
 Postoperative estrogen therapy 
stimulates endometrium regeneration with 
consequent covering of the denuded 
endometrial layer before new adhesions 
formation.  According to a systemic review 
published in 201432 and including 28 studies, 
postoperative estrogen therapy improved 
menstrual and fertility outcomes in patients 
with IUAs, regardless the stage of adhesions. 
However, and similar to IUD, it needs to be 
combined with ancillary treatment to obtain 
maximal outcomes, particularly in patients 
with moderate to severe adhesions. Although 
various protocols have been proposed, there 
is no shared consensus about the ideal 
dosage, duration of treatment and 
combination of hormones.32,60 The most 
commonly used regimen consists of estradiol 
valerate 4mg/day for at least 21 days, with 
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the addition of medroxyprogesterone acetate 
10mg for the last 7 of the 21 days.32 
 Besides hormonal therapy, other 
medical therapies have been proposed. A 
small non-randomized study published in 
201061 has shown that vitamin E 
(600mg/day orally), l-arginine (6g/day 
orally) or sildenafil citrate (100mg/day 
intravaginally) improved uterine 
vascularization and endometrial thickness in 
patients with thin endometrium. Perhaps 
these therapies could inhibit IUAs 
reformation and improve endometrial 
growth, however, they have never been 




Barrier gels prevent direct contact 
between opposing uterine walls.62 The ideal 
barrier should be non-immunogenic, stay in 
place without sutures, promote the healing of 
endometrium tissue, remain active in the 
presence of blood and be completely 
biodegradable.63,64 
Hyaluronic acid is a water-soluble 
polysaccharide composed by glucuronic acid 
and N-acetylglucosamine. Due to its 
biocompatibility, viscoelasticity and 
antiadhesive properties, hyaluronic acid and 
its derivates have been studied for IUAs 
prevention.64,65 Hyaluronic acid is not the 
ideal substance for all procedures, due to its 
limited residence time when applied to a 
surgical site and its fast metabolization.52,64 
To circumvent these disadvantages, derivates 
of hyaluronic acid have been developed. 
These substances include auto-crosslinked 
hyaluronic acid gel and combination of 
hyaluronic acid with other anti-adhesion 
components, namely carboxymethylcellulose 
and alginate. 
Auto-crosslinked hyaluronic acid gel 
is a highly viscous gel obtained through an 
internal auto-crosslinking reaction of pure 
hyaluronic gel. A recent systematic review 
and meta-analysis66 including 5 randomized 
controlled studies has shown that auto-
crosslinked hyaluronic acid gel is effective 
in the prevention of both intraperitoneal 
adhesions after laparoscopic myomectomy 
and IUAs after hysteroscopic surgery.  
Hyaluronic acid with 
carboxymethylcellulose is a well-known 
anti-adhesive material with long-lasting 
action for about 7 days.65 Alginate has also 
demonstrated efficacy in the prevention of 
intra-abdominal adhesions in an animal 
model.67 A randomized, single-blind clinical 
trial65 including 187 women with a 
surgically treatable intrauterine lesion 
(myomas, polyps, septa, IUAs or 
dysfunctional bleeding) has concluded that 
alginate carboxymethylcellulose hyaluronic 
acid (ACH) and carboxymethylcellulose 
hyaluronic acid (CH) have comparable anti-
adhesive effects. In the subgroup of women 
without baseline IUAs, ACH has actually 
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shown a lower rate of IUAs than CH. 
Importantly, there were no severe adverse 
effects related to both ACH and CH. One 
patient reported lower back pain in CH 
group and two patients reported diarrhea and 
general itching sensation, respectively, in the 
ACH group. These events were mild and 
recovered spontaneously.  
Intercoat (Oxiplex/AP gel) is a 
viscoelastic gel commonly used for 
prevention of pelvic adhesions. It is 
composed of polyethylene oxide and 
carboxymethylcellulose stabilized by 
calcium chloride.62,68,69 A randomized 
controlled study published in 201170, 
including 110 women who underwent 
hysteroscopic surgery demonstrated a 
significant reduction in the incidence of new 
IUAs in Intercoat group comparing to 
control group (6% vs. 22%, P-value < 0.05). 
Furthermore, the application of Intercoat 
seemed to reduce the severity of IUAs, with 
fewer moderate and severe IUAs at follow-
up hysteroscopy (33% vs. 92%). More 
recently, in 2014, another randomized 
controlled study62 has shown that 
intrauterine application of Intercoat after 
hysteroscopic treatment of RPOC is safe, 
with a tendency toward reduction of new 
IUAs development and toward enhanced 
reproductive outcomes when compared to 
control group, although not statistically 
significant.  
According to a 2014 systematic 
review and meta-analysis64 including 5 
studies, the use of any anti-adhesion gel 
following operative hysteroscopy decreases 
the incidence of new adhesions formation, 
comparing to no gel use (Figure 3). If new 
adhesions formation occurs, there are less 
moderate or severe adhesions (Figure 4) and 
more mild adhesions (Figure 5) by using any 
anti-adhesion gel. However, there is no 
evidence of efficacy for the outcomes of live 
birth or clinical pregnancy (Figure 6), and 
there is no data on the outcome miscarriage. 
Despite these results, the authors emphasize 
that the included studies are of very low 
quality and in a small number, with possible 
compromise of the veracity of the results. 
More well-designed and randomized studies 
are needed to assess the efficacy of anti-
adhesion barrier gels in the prevention of 
IUAs recurrence. 




Amniotic membrane graft, besides 
functioning as an anatomical barrier, 
facilitates epithelialization by acting as a 
basement membrane substrate and inhibits 
inflammation and fibrosis. Both fresh and 
dried (lyophilized) amnion grafts can be 
used with similar efficacy. However, dried 
graft holds some advantages as availability, 
prevention of cross-infection, and easier 
surgical application.71 
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A prospective randomized controlled 
trial,71 including 45 patients with AS, 
compared HAMG to intrauterine balloon 
placement. The study has found that 
adhesions grade was significantly reduced in 
the HAMG group comparing to intrauterine 
balloon group (P-value = 0.003), with a non-
statistically significant increase in uterine 
length and menstrual flow.  
HAMG is a promising anti-adhesion 
intervention, however, it has not been very 
popular in the clinical practice and evidence 
is not sufficient to recommend its utilization. 
It is not approved for intrauterine use in the 




Adult stem cells (SCs), also referred 
to as tissue-specific SCs, play important 
roles in tissue repair and reconstruction. 
They proliferate by asymmetric cell division, 
eventually differentiating into specific cell 
lineages. It had long been speculated that 
endometrial SCs existed, based on the fact 
that endometrium is a dynamic tissue 
regenerating in every menstrual cycle.72 
Finally, in 2004, adult SCs were first 
isolated from the endometrium.73 Three 
kinds of SC exist in the human 
endometrium: epithelial, mesenchymal and 
endothelial SCs. Mounting evidence has 
confirmed that there are SCs in both the 
functionalis and basalis of the human 
endometrium.74–76  
As endometrial SCs have a key role 
in maintaining tissue homeostasis, it is likely 
that their function is aberrant in disorders 
associated with inadequate endometrial 
proliferation. Specifically in AS, it is 
hypothesized that there is a loss of 
endometrial SCs, which may or may not be 
dysfunctional.77,78 Therefore, SCs therapy 
holds great promise for the treatment of this 
disorder.  
Lately, bone marrow-derived stem 
cells (BMDSCs) have also been explored as 
a new therapeutic strategy in AS. Next 
paragraphs summarize the main conclusions 
of some recent clinical trials, in both murine 
and human models, regarding BMDSCs 
therapy. 
An experimental study79 in a rat 
model, published in 2014 aimed to 
investigate the possibility that BMDSCs 
could regenerate the endometrium in AS. A 
mouse model of AS has been developed 
using a  needle to traumatize the lumen of 
both uterine horns. Immediately following 
the damage, BMDSCs or saline were 
administered. Histological analysis 3 months 
later showed  reduced fibrosis and a 
pregnancy rate of 90% in the bone marrow-
transplanted animals, compared with 30% of 
saline-treated mice. 
Another randomized controlled trial80 
in a murine model of thin endometrium, 
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induced by uterine injection of anhydrous 
ethanol, has shown that BMDSCs 
intravenous transplantation resulted in 
increased endometrial thickness when 
compared to control group (P-value < 0.01). 
It was also observed an increase in the 
number of endometrial glands and 
capillaries.  
A prospective case series81 including 
6 women with refractory AS, published in 
2014, has evaluated the role of sub-
endometrial autologous SCs implantation. 
Bone-marrow mononuclear SCs were 
implanted in sub-endometrial zone followed 
by oral estrogen therapy. Endometrial 
thickness, assessed at 3, 6, and 9 months, has 
increased significantly when compared to 
pretreatment level (P < 0.05). Also, 5 out of 
6 patients resumed menstruation.  
Taken together, the results of these 
studies indicate that BMDSCs play a key 
role in regeneration of thin and damaged 
endometrium.  This regeneration can be due 
to (1) BMDSCs incorporation in 
endometrium and trans-differentiation into 
endometrial epithelium and stroma or (2) 
BMDSCs immunomodulatory effect with 
activation of the remaining resident 
endometrial progenitor cells by providing 
growth factors.80,81 
BMDSCs expressing 
CD133/VEGFR2 represent a subpopulation 
of BMDSCs with endothelial progenitor 
capacity that contributes to 
neoangiogenesis82,83, with good results in 
pathologies such as limb ischemia, 
postmyocardial infarction, refractory angina 
and atherosclerosis.84,85 A 2016 prospective, 
non-controlled study82 including 16 women 
with AS or endometrial atrophy, tried to 
elucidate if CD133+ BMDSC therapy is a 
safe and efficient approach in these patients. 
CD133+ cells were isolated from the 
peripheral blood and instilled into the spiral 
arteries to repopulate the SC niche and 
promote endometrial reconstruction. As a 
result, endometrial thickness increased 
significantly two months after therapy (from 
an average of 4.3mm to 6.7mm, in AS 
patients). Also, there was an increase in the 
mature vessel density and in the duration/ 
intensity of menses in the first 3 months, 
with a return to the initial levels 6 months 
after the treatment. These results are 
compatible with an effective, although 
transitory, reconstruction of the 
endometrium.  
CD133+ BMDSCs therapy appears 
to be a promising therapeutic option for 
patients with IUAs. However, randomized 
controlled studies with a larger sample size 






To prevent AS it is essential to avoid 
any trauma to the uterus, especially in the 
pregnant or postpartum state. Prevention 
should be based in 3 main principles: 
(1) Expectant or medical 
management of miscarriages/RPOC should 
be preferred instead of surgical options.37,86 
(2) If surgery is needed, D&C should 
be avoided as far as possible. A systematic 
review published in 201687  reports a 
significantly higher rate of IUAs after D&C 
compared to hysteroscopic resection (30% 
vs. 13%) in the management of RPOC. 
Hysteroscopy should therefore be considered 
a safer method for diagnosis and treatment 
of RPOC. 
(3) If D&C is indeed required it 
should be performed gently, with the use of 
either suction or a blunt (not sharp) curette 





IUAs have a high negative impact on 
female fertility and pregnancy. The 
introduction of hysteroscopy, the current 
gold standard for IUAs treatment, has 
significantly improved the treatment success 
rate and the reproductive outcomes, 
comparing to the old, conventional D&C 
technique. New developments in 
hysteroscopy, namely ultrasound guidance 
and office hysteroscopy, have contributed to 
increase the safety and efficacy of the 
procedure. Due to the high rate of post-
operative adhesions re-formation, various 
methods for prevention of recurrence have 
been developed with proven efficacy, 
although more studies are needed. Finally, 
recent experimental studies highlight SCs 
therapy as a promising therapeutic option for 
AS. 
Despite the good outcomes achieved 
nowadays with the comprehensive treatment, 
primary prevention of AS should not be 
forgotten. Greater effort should be made in 
order to avoid uterine curettages, giving 






1.  Asherman JG. Amenorrhoea traumatica 
(atretica). J Obstet Gynaecol Br Emp. 
1948;55:23-30. 
2.  March CM. Management of Asherman’s 
syndrome. Reprod Biomed Online. 
2011;23(1):63-76. 
doi:10.1016/j.rbmo.2010.11.018. 
3.  Conforti A, Alviggi C, Mollo A, De Placido 
G, Magos A. The management of Asherman 
syndrome: a review of literature. Reprod Biol 
Endocrinol. 2013;11:118. doi:10.1186/1477-
7827-11-118. 
4.  Amin TN, Saridogan E, Jurkovic D. 
Ultrasound and intrauterine adhesions: a 
novel structured approach to diagnosis and 
management. Ultrasound Obstet Gynecol. 
2015;46(2):131-139. doi:10.1002/uog.14927. 
5.  Hatasaka H. Clinical Management of the 
Uterine Factor in Infertility. Clin Obstet 
Gynecol. 2011;54(4):696-709. 
doi:10.1097/GRF.0b013e3182353d68. 
6.  Schenker JG, Margalioth EJ. Intrauterine 
adhesions: an updated appraisal. Fertil Steril. 
1982;37(5):593-610. doi:10.1016/S0015-
0282(16)46268-0. 
7.  March CM. Asherman’s Syndrome. Semin 
Reprod Med. 2011;29(2):83-94. 
doi:10.1016/j.rbmo.2010.11.018. 
8.  Jamard A, Turck M, Chéret-Benoist A, 
Dreyfus M, Benoist G. Risque de synéchie 
utérine après capitonnage utérin pour 
hémorragie du post-partum. Gynécologie Obs 
Fertil. 2014;42(10):681-685. 
doi:10.1016/j.gyobfe.2014.04.013. 
9.  Ibrahim MI, Raafat TA, Ellaithy MI, Aly RT. 
Risk of postpartum uterine synechiae 
following uterine compression suturing 
during postpartum haemorrhage. Aust New 
Zeal J Obstet Gynaecol. 2013;53(1):37-45. 
doi:10.1111/ajo.12017. 
10.  Alouini S, Coly S, Mégier P, Lemaire B, 
Mesnard L, Desroches A. Multiple square 
sutures for postpartum hemorrhage: Results 
and hysteroscopic assessment. Am J Obstet 
Gynecol. 2011;205(4):335.e1-335.e6. 
doi:10.1016/j.ajog.2011.05.006. 
11.  Rasheed SM, Amin MM, Abd Ellah AH, Abo 
Elhassan AM, El Zahry MA, Wahab HA. 
Reproductive performance after conservative 
surgical treatment of postpartum hemorrhage. 
Int J Gynaecol Obstet. 2014;124(3):248-252. 
doi:10.1016/j.ijgo.2013.08.018. 
12.  Mazzon I, Favilli A, Cocco P, et al. Does cold 
loop hysteroscopic myomectomy reduce 
intrauterine adhesions? A retrospective study. 
Fertil Steril. 2014;101(1):294-298.e3. 
doi:10.1016/j.fertnstert.2013.09.032. 
13.  Yang JH, Chen MJ, Chen C Der, Chen SU, 
Ho HN, Yang YS. Optimal waiting period for 
subsequent fertility treatment after various 
hysteroscopic surgeries. Fertil Steril. 
2013;99(7):2092-2096.e3. 
doi:10.1016/j.fertnstert.2013.01.137. 
14.  Mara M, Horak P, Kubinova K, Dundr P, 
Belsan T, Kuzel D. Hysteroscopy after 
uterine fibroid embolization: Evaluation of 
intrauterine findings in 127 patients. J Obstet 
Gynaecol Res. 2012;38(5):823-831. 
doi:10.1111/j.1447-0756.2011.01782.x. 
15.  Conforti A, Krishnamurthy GB, 
Dragamestianos C, et al. Intrauterine 
adhesions after open myomectomy: an audit. 
Eur J Obstet Gynecol Reprod Biol. 
2014;179:42-45. 
doi:10.1016/j.ejogrb.2014.04.034. 
16.  Bukulmez O, Yarali H, Gurgan T. Total 
corporal synechiae due to tuberculosis carry a 
very poor prognosis following hysteroscopic 
synechialysis. Hum Reprod. 
1999;14(8):1960-1961. 
doi:10.1093/humrep/14.8.1960. 
17.  Krolikowski A, Janowski K, Larsen J V. 
Asherman syndrome caused by 




18.  The Practice Committee of the American 
Society for Reproductive Medicine. Current 
evaluation of amenorrhea. Fertil Steril. 
2006;86(4):148–155. 
doi:10.1016/j.fertnstert.2004.02.098. 
19.  Panayotidis C, Weyers S, Bosteels J, Van 
Herendael B. Intrauterine adhesions (IUA): 
Has there been progress in understanding and 
treatment over the last 20 years? Gynecol 
Surg. 2009;6(3):197-211. 
doi:10.1007/s10397-008-0421-y. 
20.  Deans R, Abbott J, Hons BMED. Review of 
Intrauterine Adhesions. J Minim Invasive 
Gynecol. 2010;17(5):555-569. 
doi:10.1016/j.jmig.2010.04.016. 
21.  Tuuli MG, Shanks A, Bernhard L, Odibo AO, 
Macones G a., Cahill A. Uterine Synechiae 




22.  Finberg H. Uterine Synechiae in Pregnancy: 
Expanded Criteria for Recognition and 
Clinical Significance in 28 Cases.pdf. J 
Ultrasound Med. 1991. 
23.  Engelbrechtsen L, Langhoff-Roos J, Kjer JJ, 
Istre O. Placenta accreta: adherent placenta 
due to Asherman syndrome. Clin case 
reports. 2015;3(3):175-178. 
doi:10.1002/ccr3.194. 
24.  Seckin B, Sarikaya E, Oruc AS, Celen S, 
Cicek N. Office hysteroscopic findings in 
patients with two, three, and four or more, 
consecutive miscarriages. Eur J Contracept 
Reprod Heal Care´. 2012;17(5):393-398. 
doi:10.3109/13625187.2012.698767. 
25.  Sylvestre C, Child TJ, Tulandi T, Tan SL. A 
prospective study to evaluate the efficacy of 
two- and three-dimensional 
sonohysterography in women with 
intrauterine lesions. Fertil Steril. 
2003;79(5):1222-1225. doi:10.1016/S0015-
0282(03)00154-7. 
26.  Seshadri S, Khalil M, Osman A, Clough A, 
Jayaprakasan K, Khalaf Y. The evolving role 
of saline infusion sonography (SIS) in 
infertility. Eur J Obstet Gynecol Reprod Biol. 
2015;185:66-73. 
doi:10.1016/j.ejogrb.2014.11.037. 
27.  Seshadri S, El-Toukhy T, Douiri A, 
Jayaprakasan K, Khalaf Y. Diagnostic 
accuracy of saline infusion sonography in the 
evaluation of uterine cavity abnormalities 
prior to assisted reproductive techniques: a 
systematic review and meta-analyses. Hum 
Reprod Update. 2015;21(2):262-274. 
doi:10.1093/humupd/dmu057. 
28.  Van Dongen H, De Kroon CD, Van Den 
Tillaart SAHM, Louwé LA, Trimbos-Kemper 
GCM, Jansen FW. A randomised comparison 
of vaginoscopic office hysteroscopy and 
saline infusion sonography: a patient 
compliance study. BJOG An Int J Obstet 
Gynaecol. 2008;115(10):1232-1237. 
doi:10.1111/j.1471-0528.2008.01858.x. 
29.  Pundir J, Pundir V, Omanwa K, Khalaf Y, El-
Toukhy T. Hysteroscopy prior to the first IVF 
cycle: A systematic review and meta-analysis. 
Reprod Biomed Online. 2014;28(2):151-161. 
doi:10.1016/j.rbmo.2013.09.025. 
30.  Buttram Jr VC Siegler A, DeCherney A, 
Gibbons W, March C. G V, American 
Fertility Society. The American Fertility 
Society classifications of adnexal adhesions, 
distal tubal occlusion, tubal occlusion 
secondary to tubal ligation, tubal pregnancies, 
mullerian anomalies and intrauterine 
adhesions. Fertil Steril. 1988;49(6):944-955. 
doi:10.1016/S0015-0282(16)59942-7. 
31.  Nasr AL, Al-Inany HG, Thabet SM, 
Aboulghar M. A clinicohysteroscopic scoring 
system of intrauterine adhesions. Gynecol 
Obs Invest. 2000;50(3):178-181. 
doi:goi50178 [pii]. 
32.  Johary J, Xue M, Zhu X, Xu D, Velu PP. 
Efficacy of Estrogen Therapy in Patients 
With Intrauterine Adhesions: Systematic 
Review. J Minim Invasive Gynecol. 
2014;21(1):44-54. 
doi:10.1016/j.jmig.2013.07.018. 
33.  Myers EM, Hurst BS. Comprehensive 
management of severe Asherman syndrome 
and amenorrhea. Fertil Steril. 
2012;97(1):160-164. 
doi:10.1016/j.fertnstert.2011.10.036. 
34.  Xiao S, Wan Y, Xue M, et al. Etiology, 
treatment, and reproductive prognosis of 
women with moderate-to-severe intrauterine 
adhesions. Int J Gynecol Obstet. 
2014;125(2):121-124. 
doi:10.1016/j.ijgo.2013.10.026. 
35.  Hanstede MMF, van der Meij E, Goedemans 
L, Emanuel MH. Results of centralized 
Asherman surgery, 2003–2013. Fertil Steril. 
2015;104(6):1561-1568.e1. 
doi:10.1016/j.fertnstert.2015.08.039. 
36.  Takai IU, Kwayabura AS, Ugwa EA, Idrissa 
A, Obed JY, Bukar M. A 10-year Review of 
the Clinical Presentation and Treatment 
Outcome of Asherman’s Syndrome at a 
Center with Limited Resources. Ann Med 
Heal Sci Res. 2015;5(6):442-446. 
doi:10.4103/2141-9248.177984. 
37.  Yu D, Med M, Wong Y, Cheong Y, Xia E. 
Asherman syndrome — one century later. 
Fertil Steril. 2008;89(4):759-779. 
doi:10.1016/j.fertnstert.2008.02.096. 
38.  Deans R, Abbott J. Review of Intrauterine 
Adhesions. J Minim Invasive Gynecol. 
2010;17(5):555-569. 
doi:10.1016/j.jmig.2010.04.016. 
39.  Song D, Liu Y, Xiao Y, Li TC, Zhou F, Xia 
E. A matched cohort study comparing the 
outcome of intrauterine adhesiolysis for 
Asherman’s syndrome after uterine artery 
embolization or surgical trauma. J Minim 
Invasive Gynecol. 2014;21(6):1022-1028. 
doi:10.1016/j.jmig.2014.04.015. 
40.  Emanuel MH. New developments in 




41.  Bahar R, Shimonovitz M, Benshushan A, 
Shushan A. Case-Control Study of 
Complications Associated With Bipolar and 
Monopolar Hysteroscopic Operations. J 
Minim Invasive Gynecol. 2013;20(3):376-
380. doi:10.1016/j.jmig.2012.12.012. 
42.  Kresowik JD, Syrop CH, Van Voorhis BJ, 
Ryan GL. Ultrasound is the optimal choice 
for guidance in difficult hysteroscopy. 
Ultrasound Obstet Gynecol. 2012;39(6):715-
718. doi:10.1002/uog.11072. 
43.  Amer MIM, Omar OH, El Sherbiny Hamed 
M, Dahroug EG. Subendometrial Blood Flow 
Changes by 3-Dimensional Power Doppler 
Ultrasound After Hysteroscopic Lysis of 
Severe Intrauterine Adhesions: Preliminary 
Study. J Minim Invasive Gynecol. 
2015;22(3):495-500. 
doi:10.1016/j.jmig.2014.12.165. 
44.  Malhotra N, Bahadur A, Kalaivani M, Mittal 
S. Changes in endometrial receptivity in 
women with Asherman’s syndrome 
undergoing hysteroscopic adhesiolysis. Arch 
Gynecol Obstet. 2012;286(2):525-530. 
doi:10.1007/s00404-012-2336-0. 
45.  Fernandez H, Peyrelevade S, Legendre G, 
Faivre E, Deffieux X, Nazac A. Total 
adhesions treated by hysteroscopy: must we 
stop at two procedures? Fertil Steril. 
2012;98(4):980-985. 
doi:10.1016/j.fertnstert.2012.06.032. 
46.  Yang J, Chen C, Chen S, Yang Y, Chen M. 
The influence of the location and extent of 
intrauterine adhesions on recurrence after 
hysteroscopic adhesiolysis. BJOG An Int J 
Obstet Gynaecol. 2015;123:618-623. 
doi:10.1111/1471-0528.13353. 
47.  Bougie O, Lortie K, Shenassa H, Chen I, 
Singh SS. Treatment of Asherman’s 
Syndrome in an Outpatient Hysteroscopy 
Setting. J Minim Invasive Gynecol. 
2015;22(3):446-450. 
doi:10.1016/j.jmig.2014.12.006. 
48.  Marsh F, Kremer C, Duffy S. Delivering an 
effective outpatient service in gynaecology. A 
randomised controlled trial analysing the cost 
of outpatient versus daycase hysteroscopy. 
BJOG An Int J Obstet Gynaecol. 
2004;111(3):243-248. doi:10.1111/j.1471-
0528.2004.00064.x. 
49.  Bougie O, Wang V, Lortie K, Shenassa H, 
Singh SS. High Patient Satisfaction with 
Office Hysteroscopy Using Tailored 
Analgesia Protocols. J Gynecol Surg. 
2014;30(2):100-104. 
doi:10.1089/gyn.2013.0067. 
50.  Van Kerkvoorde TC, Veersema S, 
Timmermans A. Long-Term Complications 
of Office Hysteroscopy: Analysis of 1028 
Cases. J Minim Invasive Gynecol. 
2012;19(4):494-497. 
doi:10.1016/j.jmig.2012.03.003. 
51.  Cooper NAM, Smith P, Khan KS, Clark TJ. 
Vaginoscopic approach to outpatient 
hysteroscopy: a systematic review of the 
effect on pain. BJOG An Int J Obstet 
Gynaecol. 2010;117(5):532-539. 
doi:10.1111/j.1471-0528.2010.02503.x. 
52.  Bosteels J, Weyers S, Kasius J, Broekmans 
FJ, Mol BW illem J, D’Hooghe TM. Anti-
adhesion therapy following operative 
hysteroscopy for treatment of female 
subfertility. Cochrane Database Syst Rev. 
2015;11(11). 
doi:10.1002/14651858.CD011110.pub2. 
53.  Lin X, Wei M, Li TC, et al. A comparison of 
intrauterine balloon, intrauterine 
contraceptive device and hyaluronic acid gel 
in the prevention of adhesion reformation 
following hysteroscopic surgery for 
Asherman syndrome: a cohort study. Eur J 
Obstet Gynecol Reprod Biol. 
2013;170(2):512-516. 
doi:10.1016/j.ejogrb.2013.07.018. 
54.  Lin XN, Zhou F, Wei ML, et al. Prospective, 
randomized, controlled trial comparing the 
efficacy of intrauterine balloon and 
intrauterine contraceptive device in the 
prevention of adhesion reformation after 
hysteroscopic adhesiolysis. Fertil Steril. 
2015;104(1):235-240. 
doi:10.1016/j.fertnstert.2015.04.008. 
55.  Gupta S, Talaulikar VS, Onwude J, 
Manyonda I. A pilot study of Foley’s catheter 
balloon for prevention of intrauterine 
adhesions following breach of uterine cavity 
in complex myoma surgery. Arch Gynecol 
Obstet. 2013;288(4):829-832. 
doi:10.1007/s00404-013-2838-4. 
56.  AAGL. AAGL Practice Report: Practice 
Guidelines for Management of Intrauterine 
Synechiae. J Minim Invasive Gynecol. 
2010;17(1):1-7. 
doi:10.1016/j.jmig.2009.10.009. 
57.  Lin YH, Jang TN, Hwang JL, et al. Bacterial 
colonization with balloon uterine stent 
placement in the uterus for 30 days: A 
randomized controlled clinical trial. Fertil 
Steril. 2014;103(2):513-518.e2. 
doi:10.1016/j.fertnstert.2014.10.032. 
58.  ACOG. ACOG Practice Bulletin No. 104: 
Antibiotic Prophylaxis for Gynecologic 
	 22	
Procedures. Obstet Gynecol. 
2009;113(5):1180-1189. 
doi:10.1097/AOG.0b013e3181a6d011. 
59.  Salma U, Xue M, Md Sayed AS, Xu D. 
Efficacy of Intrauterine Device in the 
Treatment of Intrauterine Adhesions. Biomed 
Res Int. 2014;2014. 
doi:10.1155/2014/589296. 
60.  Evans-Hoeker EA, Young SL. Endometrial 
Receptivity and Intrauterine Adhesive 
Disease. Semin Reprod Med. 2014;32(5):392-
401. doi:10.1055/s-0034-1376358. 
61.  Takasaki A, Tamura H, Miwa I, Taketani T, 
Shimamura K, Sugino N. Endometrial growth 
and uterine blood flow: a pilot study for 
improving endometrial thickness in the 
patients with a thin endometrium. Fertil 
Steril. 2010;93(6):1851-1858. 
doi:10.1016/j.fertnstert.2008.12.062. 
62.  Fuchs N, Smorgick N, Ben Ami I, et al. 
Intercoat (Oxiplex/AP Gel) for Preventing 
Intrauterine Adhesions After Operative 
Hysteroscopy for Suspected Retained 
Products of Conception: Double-Blind, 
Prospective, Randomized Pilot Study. J 
Minim Invasive Gynecol. 2014;21(1):126-
130. doi:10.1016/j.jmig.2013.07.019. 
63.  Nappi C, Di Spiezio Sardo A, Greco E, Guida 
M, Bettocchi S, Bifulco G. Prevention of 
adhesions in gynaecological endoscopy. Hum 
Reprod Update. 2007;13(4):379-394. 
doi:10.1093/humupd/dml061. 
64.  Bosteels J, Weyers S, Mol BWJ, D’Hooghe 
T. Anti-adhesion barrier gels following 
operative hysteroscopy for treating female 
infertility: a systematic review and meta-
analysis. Gynecol Surg. 2014;11(2):113-127. 
doi:10.1007/s10397-014-0832-x. 
65.  Kim T, Ahn KH, Choi DS, et al. A 
Randomized, Multi-Center, Clinical Trial to 
Assess the Efficacy and Safety of Alginate 
Carboxymethylcellulose Hyaluronic Acid 
Compared to Carboxymethylcellulose 
Hyaluronic Acid to Prevent Postoperative 
Intrauterine Adhesion. J Minim Invasive 
Gynecol. 2012;19(6):731-736. 
doi:10.1016/j.jmig.2012.08.003. 
66.  Mais V, Cirronis MG, Peiretti M, Ferrucci G, 
Cossu E, Melis GB. Efficacy of auto-
crosslinked hyaluronan gel for adhesion 
prevention in laparoscopy and hysteroscopy: 
a systematic review and meta-analysis of 
randomized controlled trials. Eur J Obstet 
Gynecol Reprod Biol. 2012;160(1):1-5. 
doi:10.1016/j.ejogrb.2011.08.002. 
67.  Hirasaki Y, Fukunaga M, Kidokoro A, et al. 
Development of a novel antiadhesive 
material, alginate flakes, ex vivo and in vivo. 
Surg Today. 2011;41(7):970-977. 
doi:10.1007/s00595-010-4410-1. 
68.  Lundorff P, Donnez J, Korell M, Audebert 
AJM, Block K, diZerega GS. Clinical 
evaluation of a viscoelastic gel for reduction 
of adhesions following gynaecological 
surgery by laparoscopy in Europe. Hum 
Reprod. 2005;20(2):514-520. 
doi:10.1093/humrep/deh651. 
69.  Schonman R, Corona R, Bastidas A, De 
Cicco C, Mailova K, Koninckx PR. Intercoat 
Gel (Oxiplex): Efficacy, Safety, and Tissue 
Response in a Laparoscopic Mouse Model. J 
Minim Invasive Gynecol. 2009;16(2):188-
194. doi:10.1016/j.jmig.2008.12.014. 
70.  Di Spiezio Sardo A, Spinelli M, Bramante S, 
et al. Efficacy of a Polyethylene Oxide-
Sodium Carboxymethylcellulose Gel in 
Prevention of Intrauterine Adhesions After 
Hysteroscopic Surgery. J Minim Invasive 
Gynecol. 2011;18(4):462-469. 
doi:10.1016/j.jmig.2011.04.007. 
71.  Amer MI, Abd-El-Maeboud KHI, Abdelfatah 
I, Salama FA, Abdallah AS. Human Amnion 
as a Temporary Biologic Barrier after 
Hysteroscopic Lysis of Severe Intrauterine 
Adhesions: Pilot Study. J Minim Invasive 
Gynecol. 2010;17(5):605-611. 
doi:10.1016/j.jmig.2010.03.019. 
72.  Xu Y, Zhu H, Zhao D, Tan J. Endometrial 
stem cells: Clinical application and 
pathological roles. Int J Clin Exp Med. 
2015;8(12):22039-22044. 
73.  Chan RWS, Schwab KE, Gargett CE. 
Clonogenicity of Human Endometrial 
Epithelial and Stromal Cells. Biol Reprod. 
2004;70(6):1738-1750. 
doi:10.1095/biolreprod.103.024109. 
74.  Gargett CE, Nguyen HPT, Ye L. Endometrial 
regeneration and endometrial stem/progenitor 
cells. Rev Endocr Metab Disord. 
2012;13(4):235-251. doi:10.1007/s11154-
012-9221-9. 
75.  Gargett CE, Masuda H. Adult stem cells in 
the endometrium. Mol Hum Reprod. 
2010;16(11):818-834. 
doi:10.1093/molehr/gaq061. 
76.  Masuda H, Matsuzaki Y, Hiratsu E, et al. 
Stem cell-like properties of the endometrial 
side population: Implication in endometrial 
regeneration. PLoS One. 2010;5(4). 
doi:10.1371/journal.pone.0010387. 
77.  Gargett CE, Schwab KE, Deane JA. 
	 23	
Endometrial stem/progenitor cells: The first 
10 years. Hum Reprod Update. 
2016;22(2):137-163. 
doi:10.1093/humupd/dmv051. 
78.  Gargett CE, Ye L. Endometrial reconstruction 
from stem cells. Fertil Steril. 2012;98(1):11-
20. doi:10.1016/j.fertnstert.2012.05.004. 
79.  Alawadhi F, Du H, Cakmak H, Taylor HS. 
Bone Marrow-Derived Stem Cell (BMDSC) 
Transplantation Improves Fertility in a 
Murine Model of Asherman’s Syndrome. 
PLoS One. 2014;9(5):e96662. 
doi:10.1371/journal.pone.0096662. 
80.  Jing Z, Qiong Z, Yonggang W, Yanping L. 
Rat bone marrow mesenchymal stem cells 
improve regeneration of thin endometrium in 
rat. Fertil Steril. 2014;101(2):587-594.e3. 
doi:10.1016/j.fertnstert.2013.10.053. 
81.  Singh N, Mohanty S, Seth T, Shankar M, 
Bhaskaran S, Dharmendra S. Autologous 
stem cell transplantation in refractory 
Asherman’s syndrome: A novel cell based 
therapy. J Hum Reprod Sci. 2014;7(2):93-98. 
doi:10.4103/0974-1208.138864. 
82.  Santamaria X, Cabanillas S, Cervelló I, et al. 
Autologous cell therapy with CD133+ bone 
marrow-derived stem cells for refractory 
Asherman’s syndrome and endometrial 
atrophy: a pilot cohort study. Hum Reprod. 
2016;31(5):1087-1096. 
doi:10.1093/humrep/dew042. 
83.  Cervelló I, Gil-Sanchis C, Santamaría X, et 
al. Human CD133+ bone marrow-derived 
stem cells promote endometrial proliferation 
in a murine model of Asherman syndrome. 
Fertil Steril. 2015;104(6):1552-60-3. 
doi:10.1016/j.fertnstert.2015.08.032. 
84.  Rafii S, Lyden D. Therapeutic stem and 
progenitor cell transplantation for organ 
vascularization and regeneration. Nat Med. 
2003;9(6):702-712. doi:10.1038/nm0603-702. 
85.  Jimenez-Quevedo P, Gonzalez-Ferrer JJ, 
Sabate M, et al. Selected CD133+ Progenitor 
Cells to Promote Angiogenesis in Patients 
With Refractory Angina - Final Results of the 
PROGENITOR Randomized Trial. Circ Res. 
2014;115(11):950-960. 
doi:10.1161/CIRCRESAHA.115.303463. 
86.  Hooker AB, Lemmers M, Thurkow AL, et al. 
Systematic review and meta-analysis of 
intrauterine adhesions after miscarriage: 
prevalence, risk factors and long-term 
reproductive outcome. Hum Reprod Update. 
2014;20(2):262-278. 
doi:10.1093/humupd/dmt045. 
87.  Hooker AB, Aydin H, Brölmann HAM, 
Huirne JAF. Long-term complications and 
reproductive outcome after the management 
of retained products of conception: A 











































Table 1 – American Fertility Society classification of IUA (1988)30 
Table 2 – Clinicohysteroscopic scoring system of IUA (2000)31 
Figure 1 – Forest plot of comparison: any therapy versus no treatment or placebo; outcome: 
presence of IUAs at second-look hysteroscopy. Adapted from Bosteels J et al. (2015)52 
Figure 2 – Forest plot of comparison: any therapy versus no treatment or placebo; outcome: live 
birth. Adapted from Bosteels J et al. (2015)52 
Figure 3 – Forest plot of comparison: any anti-adhesion gel versus no gel; outcome: incidence of 
the novo adhesions at second-look hysteroscopy. Adapted from Bosteels J et al. (2014)64 
Figure 4 – Forest plot of comparison: any anti-adhesion gel versus no gel; outcome: American 
Fertility Society (AFS) 1988 stage II (moderate) or stage III (severe) adhesions at second-look 
hysteroscopy. Adapted from Bosteels J et al. (2014)64 
Figure 5 – Forest plot of comparison: any anti-adhesion gel versus no gel; outcome: American 
Fertility Society (AFS) 1988 stage I (mild) adhesions at second-look hysteroscopy. Adapted from 
Bosteels J et al. (2014)64 
Figure 6 – Forest plot of comparison: any anti-adhesion gel versus no gel; outcome: pregnancy. 











Cavity	involved	 <1/3	 1/3	-	2/3	 >2/3	
1	 2	 3	
Type	of	adhesions	 Filmy	 Filmy	and	dense	 Dense	
1	 2	 3	
Menstrual	pattern	 Normal	 Hypomenorrhea	 Amenorrhea	
0	 2	 4	
Prognostic	classi&ication	
Stage	I	(Mild)	 1-4	
Stage	II	(Moderate)	 5-8	
Stage	III	(Severe)	 9-12	
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TABLE	2	
	
	
	
	
	 	
Score	
Hysteroscopic	,indings	
Isthmic	-ibrosis	 2	
Filmy	adhesions	 Few	 1	
Excessive	
(i.e.,	>50%	of	the	cavity)	
2	
Dense	adhesions	 Single	band	 2	
Multiple	bands	
(i.e.,	>50%	of	the	cavity)	
4	
Tubal	ostium	 Both	visualized	 0	
Only	one	visualized	 2	
Both	not	visualized	 4	
Tubular	cavity	(sound	less	than	6)	 10	
Menstrual	pattern	
Normal	 0	
Hypomenorrhea	 4	
Amenorrhea	 8	
Reproductive	performance	
Good	obstetric	history	 0	
Recurrent	pregnancy	loss	 2	
Infertility	 4	
0-4	=	mild	(good	prognosis);	5-10	=	moderate	(fair	
prognosis);	11-22	=	severe	(poor	prognosis)	
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FIGURE	3	
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FIGURE	6	
 
 
 
